Gary Doherty
@GaryJDoherty
Followers
245
Following
751
Media
2
Statuses
70
Medical Oncologist, Cambridge, UK. Any views expressed are my own and do not constitute medical advice.
Cambridge, England
Joined February 2019
Congratulations, @SamirMorsli2!.
Delighted that my recent work with @DanielMuozEspn1 and @GaryJDoherty has been published!. We discuss new tools for detecting and eliminating senescent cells, and it's my first as part of the @MunozEspin_Lab 🥳.
0
0
3
RT @MunozEspin_Lab: Twitter friends, we are recruiting! 🎉 Looking for a highly motivated Research Associate to study senescence in cancer &….
0
17
0
For those of you who also struggle with effective management of patients with adenoid cystic carcinoma, we hope this is useful. Note also encouraging interim data for AL101 in the ACCURACY trial #lcsm @BTOGORG.
Clinical researchers led by @GaryJDoherty use a personalised #PrecisionMedicine approach to treat a rare cancer of the windpipe. @CUH_NHS @East_Genomics @dePaulaBHR . 👉 News article
0
3
19
RT @MunozEspin_Lab: Hey Twitter pals, we are recruiting! 🎉 Looking for a highly motivated Research Associate to study senescence in cancer….
0
32
0
RT @MunozEspin_Lab: Our lab is recruiting! 🎉 We are looking for a highly motivated Research Associate to study senescence in cancer & novel….
0
50
0
Blueteq form now up. Available for completely resected stage IB-IIIA patients, +/- SOC adjuvant chemotherapy (application must be up to 10 weeks from surgery for no chemo, 26 weeks if chemo), PS=0/1. per ADAURA eligibility criteria. No neoadj Rx/ pre/post op RT.
Great news for patients with early stage EGFRm NSCLC - NHSE, NICE and AstraZenec reach agreement for early access to adjuvant osimertinib. First Project Orbis MHRA authorisation. Details awaited, time now to ensure our testing pathways are optimised. @EgfrUk @EGFRResisters #lcsm.
1
0
6
Great news for patients with early stage EGFRm NSCLC - NHSE, NICE and AstraZenec reach agreement for early access to adjuvant osimertinib. First Project Orbis MHRA authorisation. Details awaited, time now to ensure our testing pathways are optimised. @EgfrUk @EGFRResisters #lcsm.
1
10
35
RT @CRUKCamNeuroOnc: 📢Our Neuro-oncology Conference 2021 is open for registrations!. Join us over two afternoons on 18&19 May to hear from….
0
15
0
RT @DrJNaidoo: Durvalumab for Stage III EGFR+ NSCLC after definitive chemoRT. In this retrospective study of 37 pts we show: .- poorer PFS….
jto.org
In 2018, durvalumab was approved by the U.S. Food and Drug Administration as consolidation immunotherapy for patients with stage III NSCLC after definitive chemoradiotherapy (CRT). However, whether...
0
4
0
RT @stephensammut: Fantastic @AACR Project GENIE Winter Meeting - these large scale multinational cancer collaborations fill me with hope!….
0
1
0
RT @OTR_Cambridge: @garyjdoherty presenting on Treatment of Advanced Lung Cancer at this morning’s oncology webinar.
0
1
0
RT @AnnualReviews: Researchers from Cambridge review the genomic landscape of cancer, the use of genomic data, and the potential therapeuti….
0
11
0
RT @CRUKCamEarlyDx: Great opportunity to join the @MunozEspin_Lab as Research Associate focusing on senescence in cancer. .
0
2
0
RT @frankmccaughan: Fantastic opportunity to come and work in our great lung cancer team in Cambridge! Closing date v soon - 01 October. Ge….
0
6
0
Excited to present on brain metastases with Paul Sanghera in the @OncologyForum this morning. Chaired by Catherine McBain. Session starts at 0900 on Zoom, registrants have been sent new links after the IT issues yesterday.
1
0
8
RT @FabioGomes_Go: Very pround of this massive UK collaboration. Promissing future! @kwokleungcheung.@BreastDocUK @GaryJDoherty @bayman_nei….
ecancer.org
The care of older cancer patients in the United Kingdom Fabio Gomes1, Anna Lewis2, Rob Morris2, Ruth Parks3, Tania Kalsi4,5, Gordana Babic-Illamn4,
0
12
0
Fantastic to see this positive NICE FAD for osimertinib (finally despite interim usage being allowed by NG161!) for the first line treatment of patients with EGFRm LA/metastatic NSCLC. Great news for UK patients.
2
8
33